Prakt. lékáren. 2011; 7(1): 39-41

Huperzine A and other natural substances in treating Alzheimer's disease

PharmDr.Jan Martin, Ph.D., Mgr.Zuzana Kršková, doc.RNDr.Jaroslav Dušek, CSc.
Katedra farmakognosie, Farmaceutická fakulta v Hradci Králové

Alzheimer's disease is a progressive neurodegenerative process which affects a significant proportion of the population, particularly those

over 65 years of age. The disease is associated with deficits and disorders of a number of neurotransmitter systems, in particular the

cholinergic one. Currently, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitors appear to be the most promising

therapeutic agents. Even among naturally occurring compounds, there are inhibitors of these enzymes and many of them are more

effective than those used in the medical practice. For instance, huperzine A has more profound effects and exhibits more beneficial

pharmacokinetic properties than current medications.

Keywords: Alzheimer's disease, acetylcholinesterase, alkaloids, huperzine A

Published: February 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Martin J, Kršková Z, Dušek J. Huperzine A and other natural substances in treating Alzheimer's disease. Praktické lékárenství. 2011;7(1):39-41.
Download citation

References

  1. Ressner P. Alzheimerova choroba - diagnostika a léčba. Neurologie pro praxi 2004; 1: 11-16.
  2. Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. International Journal of Neuropsychopharmacology 2006; 9: 101-124. Go to original source... Go to PubMed...
  3. Westra P, et al. Pharmacokinetics of galanthamine (a longacting anticholinesterase drug) in anaesthetized patients. British Journal of Anaesthesia 1986; 58: 1303-1307. Go to original source... Go to PubMed...
  4. Harvey AL. The Pharmacology of galanthamine and its analogues. Pharmacology & Therapeutics 1995; 68: 113-128. Go to original source... Go to PubMed...
  5. Sramek JJ, Frackiewicz JE, Cutler RN. Review of the acetylcholinesterase inhibitor galanthamine. Expert Opinion on Investigational Drugs 2000; 9: 2393-2402. Go to original source... Go to PubMed...
  6. Lopez S, et al. Acetylcholinesterase inhibitory activity of some Amaryllidaceae alkaloids and Narcissus extracts. Life Sciences 2002; 71: 2521-2529. Go to original source... Go to PubMed...
  7. McNulty J, et al. Structure-activity studies on acetylcholinesterase inhibition in the lycorine series of Amaryllidaceae alkaloids. Bioorganic & Medicinal Chemistry Letters 2010; 20: 5290-5294. Go to original source... Go to PubMed...
  8. Berkov S, et al. Alkaloids from Galanthus nivalis. Phytochemistry 2007; 68: 1791-1798. Go to original source... Go to PubMed...
  9. Houghton PJ, et al. Choline esterase inhibitory properties of alkaloids from two Nigerian Crinum species. Phytochemistry 2004; 65: 2893-2896. Go to original source... Go to PubMed...
  10. Pagliosa LB, et al. Effect of isoquinoline alkaloids from two Hippeastrum species on in vitro acetylcholinesterase activity. Phytomedicine 2010; 17: 698-701. Go to original source... Go to PubMed...
  11. Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacologica Sinica 2006; 27: 1-6. Go to original source... Go to PubMed...
  12. Zhang JH, Fan JZ, Deng AW. A clinical study of huperzine A on mild and moderate traumatic brain injury in memory and cognitive impairment. Chinese Journal of Rehabilitation Medicine 2002; 17: 162-164.
  13. http://clinicaltrials.gov/ct2/results?term=huperzine+A (5. 5. 2010).
  14. He XC, et al. Study on dual-site inhibitors of acetylcholinesterase: Highly potent derivatives of bis- and bifunctional huperzine B. Bioorganic & Medicinal Chemistry 2007; 15: 1394-1408. Go to original source... Go to PubMed...
  15. Schott Y, et al. 6-hydroxy- and 6-methoxy-?-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorganic & Medicinal Chemistry Letters 2006; 16: 5840-5843. Go to original source... Go to PubMed...
  16. Wang B, et al. Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. European Journal of Medicinal Chemistry 2010; 45: 1415-1423. Go to original source... Go to PubMed...
  17. Castro NG, et al. CNS-selective noncompetitive cholinesterase inhibitors derived from the natural piperidine alkaloid (-) - spectaline. European Journal of Pharmacology 2008; 580: 339-349. Go to original source... Go to PubMed...
  18. Pan L, et al. Design, synthesis and evaluation of isaindigotone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors. Bioorganic & Medicinal Chemistry Letters 2008; 18: 3790-3793. Go to original source... Go to PubMed...
  19. Tang H, et al. Derivatives of oxoisoaporphine alkaloids: A novel class of selective acetylcholinesterase inhibitors. Bioorganic & Medicinal Chemistry Letters 2007; 17: 3765-3768. Go to original source... Go to PubMed...
  20. Huang L, et al. Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorganic & Medicinal Chemistry 2010; 18: 4475-4484. Go to original source... Go to PubMed...




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.